{"entity":{"id":"nct01906385","kind":"trial","name":"Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)","aka":["ReSPECT"],"tldr":"A phase 1/2 trial of Rhenium Liposome Treatment in glioma & glioblastoma, run by Cerenome, now recruiting.","summary":"Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) is a phase 1/2 interventional study registered as NCT01906385 by Cerenome, with 55 participants planned, started 2015-06-03 and due to reach its primary completion in 2025-12. Interventions recorded: Rhenium Liposome Treatment.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01906385","url":"https://clinicaltrials.gov/study/NCT01906385"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mays-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01906385","phase":"1/2","setting":"A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)","sponsor":"Cerenome","started":"2015-06-03","startedType":"actual","enrolled":55,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct01906385/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"institution":[{"id":"mays-cancer-center","kind":"institution","name":"Mays Cancer Center at UT Health San Antonio","route":"/institutions/mays-cancer-center/"}]}}